A randomized, open-label, 3-way crossover study to assess the pharmacokinetic drug interactions between DS-8500a and a hypoglycemic agent (glimepiride or repaglinide) in Japanese healthy subjects

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223178

Enrollment

Registered

2016-04-22

Start date

2016-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

investigational material(s) Generic name etc : DS-8500a INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Japanese 2)Persons who provided written informed consent before the screening examination 3)Persons >= 20 years and == 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination

Exclusion criteria

Exclusion criteria: 1)Persons with hypersensitivity or idiosyncratic reactions to a drug, (such as penicillin allergy) 2)Persons with drug or alcohol dependence

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics and safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026